DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06659159

GLP-1

Not yet recruiting

Effects of Beginning a GLP1-Agonist Therapy on Residual Gastric Content and Gastric Emptying

Effects of Beginning a GLP1-Agonist Therapy on Residual Gastric Content and Gastric Emptying: a Prospective Ultrasound Approach with Focus on Perioperative Aspiration Risk.

Lead sponsor

Sascha Battig

Asset

GLP-1 / incretin class catch-all

Listed sites

0

Recruiting sites

—

Enrollment

50

estimated

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Gastric content

Identifiers

Registered as

NCT IDNCT06659159
Org study IDEffects of beginning a GLP1
Secondary IDHirslanden KlinikHirslanden Klinik, Zurich

Timeline

Milestones

Study first posted2024-10-26actual
Last update posted2024-10-26actual
Study start2024-11-01estimated
Primary completion2026-10-31estimated
Study completion2026-12-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

GLP-1 Therapy

Inclusion criteria

•Beginning a new treatment with GLP-1 Agonists. Indication and prescription determined by an endocrinologist/obesity specialist
•Signed informed consent

Exclusion criteria

•Known pregnancy, known lactation
•Underage (< 18 years)
•Absence of informed consent (missing or inability to provide)
•Anomalies of the gastrointestinal tract
•Known illnesses of the gastrointestinal tract
•Previous surgery of the gastrointestinal tract
•Elevated risk for hypoglycaemia (Sulfonylurea or Insulin)
•No investigator with completed structural education in gastric sonography is available
•Lack of intention to respect the fasting intervals and predefined standardised meals for the sonographic examination

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
4
Other clinical outcomes
2
Other (unclassified)
2
Weight & body composition
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

BMI

Time frame:baseline examination at the first endocrinologic appointment the second examination/data collection will be at the regular endocrinologic control examination 6-8 weeks after therapy initiation. Final examination is 5 months after therapy start

descriptive, improvement

Safety / tolerability / PK

4 endpoints
Secondary/protocol endpoint

Gallbladder stones

Time frame:baseline examination at the first endocrinologic appointment the second examination/data collection will be at the regular endocrinologic control examination 6-8 weeks after therapy initiation. Final examination is 5 months after therapy start

Gallbladder event

categorical status, event

Secondary/protocol endpoint

Side effects GLP-1

Time frame:baseline examination at the first endocrinologic appointment the second examination/data collection will be at the regular endocrinologic control examination 6-8 weeks after therapy initiation. Final examination is 5 months after therapy start

Treatment-emergent AEs (any)

descriptive

Secondary/protocol endpoint

Discontinuation GLP-1

Time frame:baseline examination at the first endocrinologic appointment the second examination/data collection will be at the regular endocrinologic control examination 6-8 weeks after therapy initiation. Final examination is 5 months after therapy start

Discontinuation due to AE

event count, event

Secondary/protocol endpoint

Co-medication

Time frame:baseline examination at the first endocrinologic appointment the second examination/data collection will be at the regular endocrinologic control examination 6-8 weeks after therapy initiation. Final examination is 5 months after therapy start

descriptive

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Gastric content

Time frame:baseline examination at the first endocrinologic appointment the second examination/data collection will be at the regular endocrinologic control examination 6-8 weeks after therapy initiation. Final examination is 5 months after therapy start

change from baseline, descriptive

Secondary/protocol endpoint

Gastric emptying time

Time frame:baseline examination at the first endocrinologic appointment the second examination/data collection will be at the regular endocrinologic control examination 6-8 weeks after therapy initiation. Final examination is 5 months after therapy start

change from baseline, descriptive

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Number of empty stomachs

Time frame:baseline examination at the first endocrinologic appointment the second examination/data collection will be at the regular endocrinologic control examination 6-8 weeks after therapy initiation. Final examination is 5 months after therapy start

event count, descriptive

Secondary/protocol endpoint/low confidence

Co-morbidities

Time frame:At the baseline examination at the first endocrinologic appointment

descriptive

Publications (10)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.